- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00810199
A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment
Randomized Placebo-controlled Study of Two Treatment Strategies Based on Tocilizumab (TCZ) With or Without Methotrexate (MTX) and Possible Addition of Other Disease-modifying Anti-rheumatic Drugs (DMARDs) in Patients...
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
MG
-
Belo Horizonte, MG, Brazil, 30130-100
-
-
RS
-
Porto Alegre, RS, Brazil, 90035-903
-
-
SP
-
Sao Paulo, SP, Brazil, 05403-000
-
Sao Paulo, SP, Brazil, 04026-000
-
Sao Paulo, SP, Brazil, 04039-004
-
-
-
-
-
Rijeka, Croatia, 51000
-
Zagreb, Croatia, 10000
-
-
-
-
-
Frederiksberg, Denmark, 2000
-
Hellerup, Denmark, 2900
-
Køge, Denmark, 4600
-
-
-
-
-
Tallinn, Estonia, 11312
-
Tallinn, Estonia, 13419
-
-
-
-
-
Abbeville, France, 80142
-
Boulogne-billancourt, France, 92104
-
Brest, France, 29609
-
Echirolles, France, 38434
-
Le Kremlin Bicetre, France, 94275
-
Le Mans, France, 72037
-
Marseille, France, 13285
-
Marseille, France, 13385
-
Monaco, France, 98012
-
Nantes, France, 44035
-
Nice, France, 06202
-
Paris, France, 75571
-
Paris, France, 75679
-
Pierre Benite, France, 69495
-
Vandoeuvre-les-nancy, France, 54511
-
-
-
-
-
Aachen, Germany, 52064
-
Berlin, Germany, 10117
-
Berlin, Germany, 13125
-
Dresden, Germany, 01307
-
Erlangen, Germany, 91054
-
Hamburg, Germany, 22081
-
Jena, Germany, 07747
-
Köln, Germany, 50924
-
Muenchen, Germany, 80336
-
Ratingen, Germany, 40882
-
Wuerzburg, Germany, 97080
-
-
-
-
-
Athens, Greece, 11527
-
Thessaloniki, Greece, 54642
-
Thessaloniki, Greece, 54636
-
-
-
-
-
Afula, Israel, 18101
-
Beer Sheva, Israel, 8410101
-
Haifa, Israel, 31048
-
Haifa, Israel, 34362
-
Haifa, Israel, 34354
-
Kfar Saba, Israel, 44281
-
Ramat-Gan, Israel, 52621
-
Rishon Lezion, Israel
-
Tel Aviv, Israel, 6423906
-
-
-
-
-
Ancona, Italy, 60020
-
Bari, Italy, 70124
-
Perugia, Italy, 06122
-
Prato, Italy, 59100
-
Roma, Italy, 00168
-
-
-
-
-
Bauska, Latvia, 3901
-
Daugavpils, Latvia, 5417
-
Liepaja, Latvia, 3400
-
Riga, Latvia, LV-1002
-
Riga, Latvia, 1038
-
Riga, Latvia, 1006
-
-
-
-
-
Amsterdam, Netherlands, 1105 AZ
-
Amsterdam, Netherlands, 1081 HV
-
Leiden, Netherlands, 2333 ZA
-
Maastricht, Netherlands, 6202 AZ
-
Nijmegen, Netherlands, 6525 GA
-
Utrecht, Netherlands, 3584 CX
-
-
-
-
-
Drammen, Norway, 3004
-
Gjettum, Norway, 1346
-
Kristiansand, Norway, 4604
-
Lillehammer, Norway, 2609
-
Moss, Norway, 1535
-
Oslo, Norway, 0319
-
-
-
-
-
Bucharest, Romania, 011172
-
Bucuresti, Romania, 020983
-
-
-
-
-
Barnaul, Russian Federation, 656024
-
Ekaterinburg, Russian Federation, 620102
-
Irkutsk, Russian Federation, 664047
-
Izhevsk, Russian Federation, 426009
-
Kazan, Russian Federation, 420012
-
Khanty-Mansiysk, Russian Federation, 628011
-
Kursk, Russian Federation, 305007
-
Moscow, Russian Federation, 115522
-
Novosibirsk, Russian Federation, 630117
-
Novosibirsk, Russian Federation, 630099
-
St Petersburg, Russian Federation, 191015
-
Tjumen, Russian Federation, 625023
-
UFA, Russian Federation, 450005
-
Ulyanovsk, Russian Federation, 432063
-
Vladivostok, Russian Federation, 690105
-
-
-
-
-
Belgrade, Serbia, 11000
-
Kragujevac, Serbia, 34000
-
Niska Banja, Serbia, 18250
-
Nova sad, Serbia, 21000
-
-
-
-
-
Barcelona, Spain, 08003
-
Madrid, Spain, 28046
-
Madrid, Spain, 28041
-
Madrid, Spain, 28007
-
Madrid, Spain, 28222
-
Sevilla, Spain, 41009
-
-
Asturias
-
Oviedo, Asturias, Spain, 33006
-
-
La Coruña
-
La Coruna, La Coruña, Spain, 15006
-
Santiago De Compostela, La Coruña, Spain, 15706
-
-
Madrid
-
Leganes, Madrid, Spain, 28191
-
-
Vizcaya
-
Bilbao, Vizcaya, Spain, 48013
-
-
-
-
-
Goeteborg, Sweden, 41345
-
Umea, Sweden, 90185
-
-
-
-
-
Bangkok, Thailand, 10300
-
Khon Kaen, Thailand, 40002
-
Pathumthani, Thailand, 12120
-
-
-
-
-
Cannock, United Kingdom, WS11 5XY
-
Glasgow, United Kingdom, G12 0YN
-
Leeds, United Kingdom, LS7 4SA
-
London, United Kingdom, SE5 9RS
-
Newcastle-upon-Tyne, United Kingdom, NE2 4HH
-
Norwich, United Kingdom, NR4 7UY
-
-
-
-
California
-
Santa Monica, California, United States, 90404
-
Upland, California, United States, 91786
-
Whittier, California, United States, 90606
-
-
Florida
-
Aventura, Florida, United States, 33180
-
Naples, Florida, United States, 34102
-
Orange Park, Florida, United States, 32073
-
Plantation, Florida, United States, 33317
-
Sarasota, Florida, United States, 34239
-
South Miami, Florida, United States, 33143
-
Tamarac, Florida, United States, 33321
-
-
Minnesota
-
Eagan, Minnesota, United States, 55121
-
-
Nevada
-
Las Vegas, Nevada, United States, 89128
-
-
Ohio
-
Mayfield, Ohio, United States, 44143
-
Middleburg Heights, Ohio, United States, 44130
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
-
-
Pennsylvania
-
West Reading, Pennsylvania, United States, 19611
-
-
South Carolina
-
Greenville, South Carolina, United States, 29601
-
-
Tennessee
-
Nashville, Tennessee, United States, 37205
-
-
Texas
-
Houston, Texas, United States, 77004
-
San Antonio, Texas, United States, 78217
-
-
Washington
-
Spokane, Washington, United States, 99204
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- adult patients, ≥ 18 years of age;
- moderate to severe active rheumatoid arthritis (Disease Activity Score (DAS28) > 4.4);
- inadequate response to methotrexate;
- on a stable dose of ≥ 15mg/week methotrexate for at least 6 weeks.
Exclusion Criteria:
- prior treatment with a biologic;
- Rheumatoid arthritis (RA) functional class IV;
- known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections;
- evidence of active malignant disease.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tocilizumab + Methotrexate
Tocilizumab 8 mg/kg (up to 800 mg) intravenous (IV) once every 4 weeks + weekly oral methotrexate continuing at the patient's pre-study dose for 24 weeks.
Patients taking oral corticosteroids remained on their pre-study dose (up to 10 mg/day).
Week 24 to Week 52 the dose of tocilizumab and methotrexate remained the same.
Based on DAS28 assessments, corticosteroid dose was adjusted and disease-modifying antirheumatic drugs (DMARDS) added.
Week 52 to Week 104, based on the DAS28 assessment, treatment was adjusted to one of four protocol specified treatment regimens: Treatment tapering, Continued treatment, Treatment intensification or Maintenance treatment.
After Week 100, patients who discontinued tocilizumab because of remission were retreated with the last effective dose of tocilizumab or blinded methotrexate if a flare occurred.
|
tocilizumab 8 mg IV every 4 weeks.
Other Names:
Approximately 15-17 mg methotrexate capsule orally once a week.
|
Placebo Comparator: Tocilizumab + Placebo
Tocilizumab 8 mg/kg (up to 800 mg) IV once every 4 weeks + weekly oral placebo to methotrexate continuing at the patient's pre-study dose for 24 weeks.
Patients taking oral corticosteroids remained on their pre-study dose (up to 10 mg/day).
Week 24 to Week 52 the dose of tocilizumab and placebo to methotrexate remained the same.
Based on DAS28 assessments, corticosteroid dose was adjusted and disease-modifying antirheumatic drug (DMARDS) added.
Week 52 to Week 104, based on the DAS28 assessment, treatment was adjusted to one of four protocol specified treatment regimens: Treatment tapering, Continued treatment, Treatment intensification or Maintenance treatment.
After Week 100, patients who discontinued tocilizumab because of remission were retreated with the last effective dose of tocilizumab or blinded placebo to methotrexate if a flare occurred.
|
tocilizumab 8 mg IV every 4 weeks.
Other Names:
Placebo matching methotrexate capsule taken orally once a week.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Disease Activity Score 28 Joints (DAS28) Remission at Week 24
Time Frame: Week 24
|
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) [28 joints], swollen joint count (SJC) [28 joints], patient's global assessment of disease activity [visual analog scale: 0=no disease activity to 100=maximum disease activity] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control.
DAS28 Remission is defined as a DAS28 score < 2.6.
|
Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With American College of Rheumatology (ACR20) Response
Time Frame: Baseline, Weeks 24, 52, 104
|
ACR20 response is defined as a ≥ 20% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant [either C-reactive protein or Erythrocyte Sedimentation Rate].
|
Baseline, Weeks 24, 52, 104
|
Percentage of Participants With ACR50 Response
Time Frame: Baseline, Weeks 24, 52, 104
|
ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant [either C-reactive protein or Erythrocyte Sedimentation Rate].
|
Baseline, Weeks 24, 52, 104
|
Percentage of Participants With ACR70 Response
Time Frame: Baseline, Weeks 24, 52, 104
|
ACR70 response is defined as a ≥ 70% improvement (reduction) compared with Baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant [either C-reactive protein or Erythrocyte Sedimentation Rate].
|
Baseline, Weeks 24, 52, 104
|
Percentage of Participants With ACR90 Response
Time Frame: Baseline, Weeks 24, 52, 104
|
ACR90 response is defined as a ≥ 90% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant [either C-reactive protein or Erythrocyte Sedimentation Rate].
|
Baseline, Weeks 24, 52, 104
|
Time to First ACR20 Response
Time Frame: 104 Weeks
|
Time in days from first administration of study drug until ACR20 response.
ACR20 response is defined as a ≥ 20% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant [either C-reactive protein or Erythrocyte Sedimentation Rate].
|
104 Weeks
|
Time to First ACR50 Response
Time Frame: 104 Weeks
|
Time in days from first administration of study drug until ACR50 response.
ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant [either C-reactive protein or Erythrocyte Sedimentation Rate).
|
104 Weeks
|
Time to First ACR70 Response
Time Frame: 104 Weeks
|
Time in days from first administration of study drug until ACR70 response.
ACR70 response is defined as a ≥ 70% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant [either C-reactive protein or Erythrocyte Sedimentation Rate].
|
104 Weeks
|
Time to First ACR90 Response
Time Frame: 104 Weeks
|
Time in days from first administration of study drug until ACR90 response.
ACR90 response is defined as a ≥ 90% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant [either C-reactive protein or Erythrocyte Sedimentation Rate].
|
104 Weeks
|
Area Under Curve (AUC) DAS28
Time Frame: Baseline to Week 24
|
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) [28 joints], swollen joint count (SJC) [28 joints], patient's global assessment of disease activity [visual analog scale: 0=no disease activity to 100=maximum disease activity] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control.
AUC DAS28 was averaged over study days.
Analysis of Covariance was adjusted for Baseline DAS28 as a covariate and treatment group and region as fixed factors.
Higher calculated AUC values are worse (indicate higher disease activity).
|
Baseline to Week 24
|
Percentage of Participants With Disease Activity Score 28 (DAS28) Remission
Time Frame: Week 52
|
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) [28 joints], swollen joint count (SJC) [28 joints], patient's global assessment of disease activity [visual analog scale: 0=no disease activity to 100=maximum disease activity] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control.
DAS28 Remission is defined as a DAS28 score < 2.6.
|
Week 52
|
Percentage of Participants With DAS28 Low Disease Activity (LDAS)
Time Frame: Weeks 24, 52
|
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) [28 joints], swollen joint count (SJC) [28 joints], patient's global assessment of disease activity [visual analog scale: 0=no disease activity to 100=maximum disease activity] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control.
LDAS is defined as DAS28 ≤ 3.2.
|
Weeks 24, 52
|
Change From Baseline in DAS28 Score
Time Frame: Baseline, Weeks 24, 52
|
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) [28 joints], swollen joint count (SJC) [28 joints], patient's global assessment of disease activity [visual analog scale: 0=no disease activity to 100=maximum disease activity] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control.
A higher value indicated higher disease activity.
A negative change from Baseline indicated improvement.
|
Baseline, Weeks 24, 52
|
Percentage of Participants With Good or Moderate European League (EULAR) DAS28 Responses
Time Frame: Baseline, 24, 52
|
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) [28 joints], swollen joint count (SJC) [28 joints], patient's global assessment of disease activity [visual analog scale: 0=no disease activity to 100=maximum disease activity] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. A negative change from Baseline indicated improvement. European League Against Rheumatism (EULAR) Good response: DAS28 ≤ 3.2 or a change from Baseline < -1.2. EULAR Moderate response: DAS28 > 3.2 to ≤ 5.1 or a change from Baseline < -0.6 to ≥ -1.2. |
Baseline, 24, 52
|
Change From Baseline in Swollen Joint Count
Time Frame: Baseline, Weeks 24, 52
|
66 joints were assessed for swelling and joints are classified as swollen/not swollen giving a total possible swollen joint count score of 0 to 66.
A negative change from Baseline indicated improvement.
|
Baseline, Weeks 24, 52
|
Change From Baseline in Tender Joint Count
Time Frame: Baseline, Weeks 24, 52
|
68 joints are assessed for tenderness and joints are classified as tender/not tender giving a total possible tender joint count score of 0 to 68.
A negative change from Baseline indicated improvement.
|
Baseline, Weeks 24, 52
|
Change From Baseline in Patient Global Assessment of Disease Activity Visual Analog Scale (VAS)
Time Frame: Baseline, Weeks 24, 52
|
The patients global assessment of disease activity was assessed on a 0 to 100 millimeter (mm) horizontal visual analogue scale (VAS) by the patient.
The left-hand extreme of the line equals 0 mm, and was described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as "maximum disease activity" (maximum arthritis disease activity).
A negative change from Baseline indicated improvement.
|
Baseline, Weeks 24, 52
|
Change From Baseline in Physician Global Assessment of Disease Activity Visual Analog Scale (VAS)
Time Frame: Baseline, Weeks 24, 52
|
The physician global assessment of disease activity was assessed using a 0 to 100 mm horizontal visual analogue scale (VAS) by the physician.
The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as "maximum disease activity" (maximum arthritis disease activity).
A negative change from Baseline indicated improvement.
|
Baseline, Weeks 24, 52
|
Change From Baseline in Patient Global Assessment of Pain (VAS)
Time Frame: Baseline, Weeks 24, 52
|
The patient assessed their pain using a 0 to 100 millimeter (mm) horizontal visual analogue scale (VAS).
The left-hand extreme of the line equals 0 mm, and is described as "no pain" and the right-hand extreme equals 100 mm as "unbearable pain".
A negative change from Baseline indicated improvement.
|
Baseline, Weeks 24, 52
|
Change From Baseline in Erythrocyte Sedimentation Rate (ESR)
Time Frame: Baseline, Weeks 24, 52
|
Blood was collected for Erythrocyte Sedimentation Rate (ESR) (a test that assesses tissue inflammation) and was analyzed at a local laboratory.
ESR was measured in millimeters/hour (mm/hr).
A reduction in the level is considered an improvement.
|
Baseline, Weeks 24, 52
|
Change From Baseline in C-Reactive Protein (CRP)
Time Frame: Baseline, Weeks 24, 52
|
Blood was collected for C-Reactive Protein (CRP) (a test for analysis of inflammatory and infectious disorders) and was analyzed at a central laboratory.
The serum concentration of CRP was measured in milligrams/deciliter (mg/dL).
A reduction in the level is considered an improvement.
|
Baseline, Weeks 24, 52
|
Change From Baseline in the Health Assessment Questionnaire Disability Index
Time Frame: Baseline, Weeks 24, 52
|
The Stanford Health Assessment Questionnaire Disability Index (HAQ-DI) is a patient completed questionnaire specific for rheumatoid arthritis, consisting of 20 questions in 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip and common daily activities.
There are 4 possible responses for each question: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty and 3=unable to do.
The score for each of the domains is the highest (worst) score in each domain.
A patient must have a domain score for at least 6 of 8 domains to calculate a valid HAQ-DI score which is the sum of domain scores, divided by the number of domains that have a score for a total possible score minimum/maximum 0 (best) to 3 (worst).
A negative change from Baseline indicated improvement.
|
Baseline, Weeks 24, 52
|
Change From Baseline in Total Genant Modified Sharp Scores (GSS)
Time Frame: Baseline, Weeks 24, 52, 104
|
Radiographs were taken of each hand and foot at Baseline, Weeks 24, 52 and104 and were evaluated using the Genant modified method according to Sharp.
Erosion Score: A total of 14 locations in each hand and wrist and 6 joints in the foot were evaluated for erosion using an 8-point scale where 0=Normal to 3.5=very severe erosion.
Joint Narrowing Score: A total of 13 locations in each hand and wrist and 6 joints in the foot were evaluated for joint narrowing score using a 9-point scale where 0=Normal to 4.0=definite ankylosis (stiffness or fixation of a joint).
The maximum total erosion score in the hands is 98 and in the feet 42.
The maximum scores for joint space narrowing (JSN) in the hands was104 and in the feet 48.
The total score was the sum of scores for erosions and JSN.
The maximum total modified GSS was 292.
A lower number change from Baseline was better.
Analysis of covariance model, with Baseline DAS28 as a covariate and treatment and site as fixed factors.
|
Baseline, Weeks 24, 52, 104
|
Change From Baseline in Joint Space Narrowing Score
Time Frame: Baseline, Weeks 24, 52, 104
|
A total of 13 locations in each hand and wrist and 6 joints in the foot were evaluated for joint narrowing score using a 9-point scale where 0=Normal to 4.0=definite ankylosis (stiffness or fixation of a joint).
The maximum scores for joint space narrowing (JSN) in the hands was 104 and in the feet 48 for a total possible score of 0 to 152.
A lower change from Baseline indicated a better score.
Analysis of covariance model included baseline x-ray and DAS28 as covariates and treatment group and region as fixed effects.
|
Baseline, Weeks 24, 52, 104
|
Change From Baseline in Erosion Score
Time Frame: Baseline, Weeks 24, 52, 104
|
A total of 14 locations in each hand and wrist and 6 joints in the foot were evaluated for erosion using an 8-point scale where 0=Normal to 3.5=very severe erosion.
The maximum erosion score in the hands was 98 and in the feet 42 for a total possible score of 0 to 140.
A lower number change from Baseline indicated a better score.
|
Baseline, Weeks 24, 52, 104
|
Percentage of Participants Discontinuing Tocilizumab Due to Remission
Time Frame: Weeks 52, 104
|
The percentage of participants who stopped treatment with tocilizumab due to remission.
|
Weeks 52, 104
|
Percentage of Participants Who Withdrew Due to Lack of Sufficient Therapeutic Response
Time Frame: Up to 3 years
|
Lack of Sufficient Therapeutic Response was defined as the patient not responding to the drug as expected.
|
Up to 3 years
|
Percentage of Participants Who Withdrew Due to Safety Reasons
Time Frame: Up to 3 years
|
Safety reasons were defined as adverse events, intercurrent illness or death.
An adverse event was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug.
Preexisting conditions that worsened during the study were reported as adverse events.
|
Up to 3 years
|
Change From Baseline in Rheumatoid Arthritis Quality of Life Questionnaire (RAQoL)
Time Frame: Baseline, Weeks 24, 52, 104
|
The RAQoL is a disease specific patient-reported outcome measure that determines the effect rheumatoid arthritis has on a patient's quality of life consisting of 30 questions that are answered either yes=1 or no=0 for a total possible score ranging from 0 (best) to 30 (worst).
A negative change from Baseline indicated improvement.
|
Baseline, Weeks 24, 52, 104
|
Change From Baseline in Academic Medical Center (AMC) Linear Disability Scale (ALDS)
Time Frame: Baseline, Weeks 104
|
The Academic Medical Center (AMC) Linear Disability Score (ALDS) evaluates the participant's ability to perform activities of daily life consisting of 77 questions answered yes or no .
The question difficulty and the patient's ability are arranged on a single hierarchical linear scale.
ALDS scores range from 10 to 90 with a higher score representing higher functional status.
A positive change from Baseline indicated improvement.
|
Baseline, Weeks 104
|
Area Under the Curve (AUC) From Baseline to Week 24 for ACR Response
Time Frame: Baseline to Week 24
|
ACR response was defined as an improvement (reduction) compared with baseline for both total joint count-68 joints and swollen joint count-66 joints, and for three of five variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) where 0=no pain to 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where: 0=no disease activity to 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant [either C-reactive protein or Erythrocyte Sedimentation Rate].
Area under the curve for ACR response to Week 24 was averaged over study days.
Analysis of covariance model includes treatment group, region and baseline DAS28 (≤ 5.5 and > 5.5) as fixed factors.
|
Baseline to Week 24
|
Area Under the Curve (AUC) From Baseline to Week 52 for ACR Response
Time Frame: Baseline to Week 52
|
ACR response was defined as an improvement (reduction) compared with baseline for both total joint count-68 joints and swollen joint count-66 joints, and for three of five variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) where 0=no pain to 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where: 0=no disease activity to 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant [either C-reactive protein or Erythrocyte Sedimentation Rate].Area under the curve for ACR response to Week 52 averaged over study days.
Analysis of covariance model includes treatment group, region and baseline DAS28 (<=5.5 and >5.5) as fixed factors.
|
Baseline to Week 52
|
Time to Tocilizumab Remission
Time Frame: 104 Weeks
|
The time in days from initial study drug treatment to tocilizumab remission that occurred when the patient discontinued treatment with tocilizumab.
|
104 Weeks
|
Time to Drug-Free Remission
Time Frame: 104 Weeks
|
The time in days from initial study drug treatment to drug free remission that occurred when the participant was able to discontinue tocilizumab, methotrexate/placebo and open label disease-modifying antirheumatic drugs (DMARDS).
|
104 Weeks
|
Time to Flare After Tocilizumab Remission
Time Frame: 104 Weeks
|
The time in days to a flare (recurrence of disease symptoms) after the patient discontinued treatment with tocilizumab.
|
104 Weeks
|
Time to Restart of Treatment After Discontinuation/Remission
Time Frame: 104 Weeks
|
The time in days from treatment discontinuation or remission to the restart of treatment.
|
104 Weeks
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Dougados M, Kissel K, Sheeran T, Tak PP, Conaghan PG, Mola EM, Schett G, Amital H, Navarro-Sarabia F, Hou A, Bernasconi C, Huizinga TW. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis. 2013 Jan;72(1):43-50. doi: 10.1136/annrheumdis-2011-201282. Epub 2012 May 5.
- Dougados M, Kissel K, Conaghan PG, Mola EM, Schett G, Gerli R, Hansen MS, Amital H, Xavier RM, Troum O, Bernasconi C, Huizinga TW. Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis. 2014 May;73(5):803-9. doi: 10.1136/annrheumdis-2013-204761. Epub 2014 Jan 28.
- Dougados M, Huizinga TW, Choy EH, Bingham CO 3rd, Aassi M, Bernasconi C. Evaluation of the Disease Activity Score in Twenty-Eight Joints-Based Flare Definitions in Rheumatoid Arthritis: Data From a Three-Year Clinical Trial. Arthritis Care Res (Hoboken). 2015 Dec;67(12):1762-6. doi: 10.1002/acr.22633.
- Huizinga TW, Conaghan PG, Martin-Mola E, Schett G, Amital H, Xavier RM, Troum O, Aassi M, Bernasconi C, Dougados M. Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study. Ann Rheum Dis. 2015 Jan;74(1):35-43. doi: 10.1136/annrheumdis-2014-205752. Epub 2014 Aug 28.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Autoimmune Diseases
- Joint Diseases
- Musculoskeletal Diseases
- Rheumatic Diseases
- Connective Tissue Diseases
- Arthritis
- Arthritis, Rheumatoid
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Dermatologic Agents
- Reproductive Control Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Methotrexate
Other Study ID Numbers
- MA21488
- 2008-001847-20
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
National Institute of Arthritis and Musculoskeletal...Children's Hospital Medical Center, CincinnatiCompleted
-
University of PittsburghNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedRheumatoid Arthritis | Juvenile Rheumatoid ArthritisUnited States
-
University of Missouri-ColumbiaCompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
Universidad Autonoma de Nuevo LeonCompletedRheumatoId ArthritisMexico
-
Hamad Medical CorporationUnknownRHEUMATOID ARTHRITISQatar
Clinical Trials on tocilizumab [RoActemra/Actemra]
-
Hoffmann-La RocheCompletedRheumatoid ArthritisKazakhstan
-
Hoffmann-La RocheCompleted
-
Hoffmann-La RocheCompletedRheumatoid ArthritisRussian Federation
-
Hoffmann-La RocheCompleted
-
Hoffmann-La RocheTerminatedJuvenile Idiopathic ArthritisRussian Federation, Poland
-
Hoffmann-La RocheCompleted
-
Hoffmann-La RocheCompletedJuvenile Idiopathic ArthritisSpain, Mexico, Germany, United States, Russian Federation, Australia, Italy, Argentina, Brazil, Canada, France, United Kingdom
-
Hoffmann-La RocheCompleted
-
Hoffmann-La RocheCompleted
-
Hoffmann-La RocheCompletedRheumatoid ArthritisBelgium, Czech Republic, France, Italy, Spain, Sweden, United Kingdom, Canada, Greece, Ireland, Portugal, Turkey, Netherlands, Denmark, Finland, Germany, Luxembourg, Austria, Switzerland, Poland, Australia, Hungary, Saudi Arabia, Romania and more